Anti-Human CD20 – Purified in vivo GOLD™ Functional Grade

Human tonsillar B cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

CyTOF®

Clone 2H7 recognizes an epitope on human CD20.

CD20 is a 33-37 kD transmembrane-spanning phosphoprotein that facilitates optimal B-cell immune response against T-independent antigens. It can exist in a complex with MHC class I, MHC class II, CD53, CD81, and CD82. However, CD20 can also form homo-oligomers. It has been suggested that homo-oligomerization of CD20 forms calcium ion channels in the plasma membrane of B cells. CD20 can be useful in diagnosing B-cell lymphomas and leukemias, and is the target of mAbs in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. Interestingly, studies show a link between the immune system's B cells and diabetes mellitus in which anti-CD20 antibodies rendered the T cell antibodies dysfunctional and, hence, unable to cause insulin desensitivity by a B cell antibody-modulated autoimmune response.

CD20 is present on human pre B lymphocytes and on B lymphocytes, except on plasma cells, and is expressed in tandem with surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset.

Src family tyrosine kinases, MHC class I, II, CD53, CD81, CD82

B cell activation

1. Stashenko, P. et al. (1980) J. Immunol. 125:1678
2. Fang, D. et al. (2005) Cancer Res. 65:9328
3. Bubien, J. K. et al. (1993) J. Cell Biol. 121:1121
4. White, M. W. et al. (1991) J. Immunol. 146:846
5. Cragg, M. S. et al. (2005) Curr. Dir. Autoimmun. 8:140